Oncology – Page 4

Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET

By MedXY 06/15/2026

TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.

news Oncology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

By MedXY 06/11/2026

This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.

news Oncology Respiratory

Blood Cancer Proteins Plus Histoplasma Antibodies Improve Malignancy Assessment in Indeterminate Pulmonary Nodules

By MedXY 06/11/2026

In two US cohorts, combining serum cancer biomarkers and Histoplasma antibodies with the Mayo model improved discrimination of benign versus malignant pulmonary nodules, especially in intermediate-risk cases.

news OB/GYN & Women’s Health Oncology

Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial

By MedXY 06/11/2026

A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized quality-of-life measures may underestimate.

Diabetes & Endocrinology news Oncology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

By MedXY 06/10/2026

A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/10/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

news Oncology Public Health

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations

By MedXY 06/10/2026

Population-based testing for breast cancer pathogenic variants identified many women who would not have been flagged by clinical or polygenic risk models, supporting its role in risk-based screening.

news Oncology Psychiatry

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer

By MedXY 06/10/2026

A large study of veterans with cancer found persistent risk of suicidal self-directed violence, especially in younger, unmarried, frail, or mentally ill patients and those with central nervous system, head and neck, or thyroid cancers.

Gastroenterology news Oncology

Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial

By MedXY 06/10/2026

A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.

news Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial

By MedXY 06/10/2026

Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.

news Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial

By MedXY 06/10/2026

A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.

news Oncology

The Oncology Care Model and Starting Systemic Therapy for Cancer

By MedXY 06/10/2026

A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.

news Oncology Public Health

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study

By MedXY 06/09/2026

This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.

Hematology-Oncology news Oncology

Pre-diagnostic Clonal Hematopoiesis Raises Risk of Second Cancers in Patients With Primary Cancer

By MedXY 06/08/2026

Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.

news Oncology Otorhinolaryngology

Area-Level Socioeconomic Disadvantage Is Linked to Worse Pretreatment Head and Neck Cancer–Specific Quality of Life

By MedXY 06/08/2026

In patients with head and neck cancer, living in the most socioeconomically disadvantaged areas was associated with poorer pretreatment head and neck cancer–specific quality of life, while associations with other quality-of-life domains were small and not clinically meaningful.

Clinical Updates news Oncology

Histotripsy for Neuroendocrine Liver Metastases: Early Clinical Signals, Safety Lessons, and the Road to Broader Adoption

By MedXY 06/08/2026

An early single-institution series suggests histotripsy may offer noninvasive local control for neuroendocrine liver metastases, with complete response after full-coverage treatment but important safety concerns, particularly acute kidney injury after large-volume tumor histolysis.

news OB/GYN & Women’s Health Oncology

Cold Knife Conization Was Linked to Lower Long-Term Cervical Lesion Recurrence Than LEEP in Two Real-World Cohorts

By MedXY 06/08/2026

In Swedish and Chinese cohorts, cold knife conization was associated with lower recurrent cervical lesion risk and faster HPV clearance than LEEP, although important questions remain about residual confounding, obstetric trade-offs, and procedure selection.

AI news Oncology

AI Model Shows Moderate Accuracy for Predicting Complete Response After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

By MedXY 06/08/2026

A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.

news OB/GYN & Women’s Health Oncology

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer

By MedXY 06/08/2026

In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.

Gastroenterology news Oncology

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice

By MedXY 06/07/2026

A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.